ZYGEL

Previously unknown to me Zygel came to light for me recently as indicated below:

"Zynerba Pharmaceuticals Inc.'s cannabis-derived drug Zygel improved symptoms among children and adolescents with autism spectrum disorder in a mid-stage clinical trial.Autism spectrum disorder, or ASD, is a condition related to brain development that affects communication and behaviour. This condition starts in early childhood and affects patients' functioning in society as they may have trouble with social interaction.In the U.S., approximately 1 million children and adolescents between five and 17 years old are diagnosed with ASD.Zygel is a gel formulation of a chemical compound called cannabinoid, which is derived from the plant Cannabis sativa, designed to be delivered through the skin and into the bloodstream.The trial, named Bright, involved 37 patients with ASD who were given one of two different doses of Zygel depending on their weight. Only 28 patients completed the trial, which ran for 14 weeks".

A subsequent email to Paul Gavin received a prompt response along the lines of he is familiar with both Zynerba and Zygel.The Zynerba team tried Zygel for osteoarthritis years ago and the study failed. They’ve subsequently repositioned it for Fragile X. Efforts to get samples of it to compare against ours were not successful.
It certainly appears to me that Paul Gavin is across all things cannabis.
Kens